Difference between revisions of "HAEM5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
(Updated)
(74 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
Welcome!
 
Welcome!
  
*For assignments, please see the "Author" column below (3rd column from left). If no name is present, volunteer to create content!
+
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 +
 
 +
*For assignments, please see the "Author" column below (highlighted blue).
 +
 
 +
*If empty (no name is present), please volunteer to create content for that disease!
 +
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 +
 
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 +
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
  
 +
<br />
 
{| class="wikitable" style="margin:auto"
 
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content</big>
+
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
 
|-
 
|-
!Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
+
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
 +
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
!Content Status (4th Edition)(Pending or Complete)
+
!Prior Content Status (4th Edition)(Pending or Complete)
!Date of Last Editor Review (4th Edition)
+
!Prior Date of Last Editor Review (4th Edition)
!Notes (4th Edition)
+
!Prior Notes (4th Edition)
 
|-
 
|-
 
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
 
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
Line 20: Line 29:
 
----<br />
 
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|-
 
|-
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
+
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
 +
|4/8/24
 +
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 46: Line 69:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 53: Line 76:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 60: Line 84:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
Line 67: Line 92:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 74: Line 100:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
 
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 81: Line 108:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Primary Myelofibrosis (PMF)
 
|Primary Myelofibrosis (PMF)
 
|T. Niroshi Senaratne, UCLA
 
|T. Niroshi Senaratne, UCLA
Line 88: Line 116:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
+
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
 +
| || || || ||FQR|| ||
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|Juvenile Myelomonocytic Leukemia (JMML)
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
 
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 99: Line 128:
 
|FQR has emailed SR several times, last 4/20/22
 
|FQR has emailed SR several times, last 4/20/22
 
|-
 
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Myeloproliferative Neoplasm (MPN), Unclassifiable
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
 
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 106: Line 136:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Cutaneous Mastocytosis
 
|Cutaneous Mastocytosis
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
 
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 113: Line 144:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
 
|Systemic Mastocytosis
 
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
+
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
 
|Complete
 
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Mast Cell Sarcoma
 
|Mast Cell Sarcoma
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
 
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 127: Line 159:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
 
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 134: Line 167:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 162: Line 196:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Myelodysplastic Syndrome (MDS) with Excess Blasts
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 169: Line 204:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 176: Line 212:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Refractory Cytopenia of Childhood
 
|Refractory Cytopenia of Childhood
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
 
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 183: Line 220:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Chronic Myelomonocytic Leukemia (CMML)
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 190: Line 228:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
 
|Linsheng Zhang, MD, PhD
 
|Linsheng Zhang, MD, PhD
Line 197: Line 236:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
 
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 204: Line 244:
 
|
 
|
 
|-
 
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
+
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
 +
| || || || ||FQR|| ||
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
 
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 213: Line 254:
 
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
 
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 229: Line 270:
 
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 245: Line 286:
 
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 261: Line 302:
 
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 277: Line 318:
 
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 293: Line 334:
 
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 309: Line 350:
 
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 325: Line 366:
 
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 357: Line 398:
 
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 373: Line 414:
 
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 389: Line 430:
 
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 421: Line 462:
 
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 437: Line 478:
 
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 453: Line 494:
 
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 469: Line 510:
 
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 485: Line 526:
 
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 501: Line 542:
 
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 517: Line 558:
 
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 533: Line 574:
 
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 549: Line 590:
 
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 564: Line 605:
 
|-
 
|-
 
|RESOLVE 4th edition AML-Related NON-WHO entities content
 
|RESOLVE 4th edition AML-Related NON-WHO entities content
|Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6
+
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
|ISSUE - FIX
+
|ISSUE- FIX
 +
 
 +
 
 +
Resolve Non-WHO entities
 
|
 
|
 
|
 
|
Line 581: Line 625:
 
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 597: Line 641:
 
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
 
|Disease
 
|Disease
|ISSUE - FIX ("This is a massive merge of all pages on the Myeloid Neoplasms with Germline Predisposition overiew page, plus new content"
+
|PENDING
 
|
 
|
 
|
 
|
Line 605: Line 649:
 
|
 
|
 
|
 
|
|
+
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
|
+
|See links from instructions on the 5th edition page
|
+
|Complete
|
+
|Most were re-reviewed by MS on 03/02/2021
|
+
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
 
|-
 
|-
 
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 629: Line 673:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 645: Line 689:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 661: Line 705:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 696: Line 740:
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
 
|Disease
 
|Disease
|ISSUE - FIX
+
|
 
|
 
|
 
|
 
|
Line 704: Line 748:
 
|
 
|
 
|
 
|
|Acute Myeloid Leukemia (AML) with Mutated FLT3 ([[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3]] ) ???No prior content on this page???  I don't think this is a WHO entity from the 4th edition.
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
 
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
Line 744: Line 788:
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
 +
|Tracy Tucker, PhD, FCCMG
 +
|4/6/24
 
|
 
|
|
+
|Pending
|
 
|
 
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 760: Line 804:
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
 +
|Tracy Tucker, PhD, FCCMG
 +
|4/6/24
 
|
 
|
|
+
|Pending
|
 
|
 
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 792: Line 836:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 808: Line 852:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 824: Line 868:
 
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 856: Line 900:
 
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
 
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 876: Line 920:
 
----<br />
 
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|-
 
|-
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
+
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
 
|Disease
 
|Disease
 
|
 
|
Line 904: Line 960:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Blastic plasmacytoid dendritic cell neoplasm
+
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 920: Line 976:
 
|Previously within myeloid section under JH/MS editors
 
|Previously within myeloid section under JH/MS editors
 
|-
 
|-
|Langerhans cell histiocytosis
+
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 936: Line 992:
 
|Date completed by author: 04/28/2022
 
|Date completed by author: 04/28/2022
 
|-
 
|-
|Langerhans cell sarcoma
+
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 952: Line 1,008:
 
|Date completed by author: 04/28/2022
 
|Date completed by author: 04/28/2022
 
|-
 
|-
|Indeterminate dendritic cell tumour
+
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
 
|Disease
 
|Disease
 
|
 
|
Line 968: Line 1,024:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Interdigitating dendritic cell sarcoma
+
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 984: Line 1,040:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Juvenile xanthogranuloma
+
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,000: Line 1,056:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Erdheim-Chester disease
+
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,016: Line 1,072:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Rosai-Dorfman Disease
+
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,032: Line 1,088:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|ALK-positive histiocytosis
+
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,048: Line 1,104:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Histiocytic sarcoma
+
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,070: Line 1,126:
 
----<br />
 
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 
----<br />
 
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|-
 
|-
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma
+
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,099: Line 1,166:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|IgG4-related disease
+
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,115: Line 1,182:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Unicentric Castleman disease
+
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,131: Line 1,198:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|Idiopathic multicentric Castleman disease
+
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,147: Line 1,214:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|KSHV/HHV8-associated multicentric Castleman disease
+
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,163: Line 1,230:
 
|Date completed by author: 01/24/2022
 
|Date completed by author: 01/24/2022
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,179: Line 1,246:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,195: Line 1,262:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,211: Line 1,278:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
 
|Disease
 
|Disease
|Holli authoring - Complete? Looks like needs more editing of tables
+
|Holli Drendel
|
 
 
|
 
|
 
|
 
|
 +
|?Complete? Looks like tables need more editing.
 
|
 
|
 
|HD
 
|HD
Line 1,227: Line 1,294:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,243: Line 1,310:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,259: Line 1,326:
 
|
 
|
 
|-
 
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,275: Line 1,342:
 
|
 
|
 
|-
 
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,291: Line 1,358:
 
|
 
|
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,307: Line 1,374:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,323: Line 1,390:
 
|
 
|
 
|-
 
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,339: Line 1,406:
 
|
 
|
 
|-
 
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion
+
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,355: Line 1,422:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,371: Line 1,438:
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
+
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,389: Line 1,456:
 
|RESOLVE 4th edition ALL-Related NON-WHO entities content
 
|RESOLVE 4th edition ALL-Related NON-WHO entities content
 
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
 
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE - FIX
+
|ISSUE- FIX
 +
 
 +
 
 +
Resolve Non-WHO entities
 
|
 
|
 
|
 
|
Line 1,403: Line 1,473:
 
|
 
|
 
|-
 
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
 +
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|Monoclonal B-cell Lymphocytosis
 +
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 +
|PENDING, 4/30/2024
 
|
 
|
|
+
|Assigned 12/19/2022 with completion date of 1/19/2023
|
 
|
 
|
 
 
|-
 
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
|
+
 
 +
Renee Eigsti, MD, Pathology Services of Kalamazoo
 +
 
 +
Honey Reddi, PhD, Belay Diagnostics
 +
| || ||Complete|| ||SG|| ||
 +
|Already converted to 5th edition
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 
|
 
|
Line 1,418: Line 1,494:
 
|
 
|
 
|-
 
|-
|Hairy cell leukaemia||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
|
+
| || || || ||SG|| ||
|*Snehal Patel, MD, PhD
+
|Hairy Cell Leukemia
|
+
|Snehal Patel, MD, PhD
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
|Splenic marginal zone lymphoma||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
|
+
| || || || ||SG|| ||
|*Snehal Patel, MD, PhD
+
|Splenic Marginal Zone Lymphoma
|
+
|Snehal Patel, MD, PhD
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
|
+
| || || || ||SG|| ||
|*Snehal Patel, MD, PhD
+
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|
+
|Snehal Patel, MD, PhD
 +
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
+
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,449: Line 1,528:
 
|
 
|
 
|
 
|
|
+
|Hairy Cell Leukemia Variant
|*Snehal Patel, MD, PhD
+
|Snehal Patel, MD, PhD
|
+
|Complete
 
|
 
|
 
|
 
|
 
|-
 
|-
|Lymphoplasmacytic lymphoma
+
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,465: Line 1,544:
 
|
 
|
 
|
 
|
|
+
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
+
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|
+
|Complete
|
+
|4/12/2023 by FQR
 
|
 
|
 
|-
 
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
+
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,481: Line 1,560:
 
|
 
|
 
|
 
|
|
+
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|
+
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
|
+
 
|
+
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
 +
|Complete
 +
|4/12/23 by FQR
 
|
 
|
 
|-
 
|-
|Primary cutaneous marginal zone lymphoma
+
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,497: Line 1,578:
 
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Nodal marginal zone lymphoma
+
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,513: Line 1,594:
 
|
 
|
 
|
 
|
|
+
|Nodal Marginal Zone Lymphoma
 
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
 
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|
+
|Complete
|
+
|5/28/2021
 
|
 
|
 
|-
 
|-
|Paediatric nodal marginal zone lymphoma
+
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,529: Line 1,610:
 
|
 
|
 
|
 
|
|
+
|Paediatric Nodal Marginal Zone Lymphoma
 
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
 
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
+
|Complete
|
+
|11/11/2020
 
|
 
|
 
|-
 
|-
|In situ follicular B-cell neoplasm
+
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
 
|Disease
 
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
|
+
|Pending
|
 
|
 
 
|
 
|
 
|SG
 
|SG
 
|
 
|
 
|
 
|
|
+
|In Situ Follicular Neoplasia
 
|Rachel D. Burnside, PhD, MBA, FACMGG
 
|Rachel D. Burnside, PhD, MBA, FACMGG
|
+
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Follicular lymphoma
+
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
 
|Disease
 
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
|
+
|Pending
|
 
|
 
 
|
 
|
 
|SG
 
|SG
 
|
 
|
|
+
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|
+
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
+
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
+
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Paediatric-type follicular lymphoma
+
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,577: Line 1,658:
 
|
 
|
 
|
 
|
|
+
|Paediatric-Type Follicular Lymphoma
 
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
 
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|
+
|Complete
|
+
|8/16/2020
 
|
 
|
 
|-
 
|-
|Duodenal-type follicular lymphoma
+
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
 
|Disease
 
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
|
+
|Pending
|
 
|
 
 
|
 
|
 
|SG
 
|SG
 
|
 
|
 
|
 
|
|
+
|Duodenal-Type Follicular Lymphoma
|
+
|No prior content
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Primary cutaneous follicle centre lymphoma
+
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,609: Line 1,690:
 
|
 
|
 
|
 
|
|
+
|Primary Cutaneous Follicle Centre Lymphoma
 
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
 
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
+
|Complete
|
+
|09/10/2022
 
|
 
|
 
|-
 
|-
|In situ mantle cell neoplasm
+
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,625: Line 1,706:
 
|
 
|
 
|
 
|
|
+
|In Situ Mantle Cell Neoplasia
 
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
 
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
+
|Complete
|
+
|7/26/2022
 
|
 
|
 
|-
 
|-
|Mantle cell lymphoma
+
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
 
|Disease
 
|Disease
|
+
|PENDING
 
|
 
|
 
|
 
|
Line 1,641: Line 1,722:
 
|
 
|
 
|
 
|
 +
|Mantle Cell Lymphoma
 +
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
 +
|Pending
 
|
 
|
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
+
|Target completion date 8/15/20
|
 
|
 
|
 
 
|-
 
|-
|Leukaemic non-nodal mantle cell lymphoma
+
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,657: Line 1,738:
 
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|<br />
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Transformations of indolent B-cell lymphomas
+
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,672: Line 1,753:
 
|SG
 
|SG
 
|
 
|
|
+
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Diffuse large B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
 
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
 +
|Pending
 
|
 
|
|
+
|Requested to update 14022022
|
 
 
|-
 
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
 
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|
+
|Complete
|
+
|24/02/2022
 
|
 
|
 
|-
 
|-
|ALK-positive large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|ALK-Positive Large B-cell Lymphoma
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
 
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
 +
|Pending
 
|
 
|
|
+
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|
 
 
|-
 
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING
|
+
| || || || ||GC|| ||
|*Afia Hasnain, MBBS, PhD
+
|Large B-cell Lymphoma with IRF4 Rearrangement
|
+
|Afia Hasnain, MBBS, PhD
|
+
|Complete
 +
|5/26/2021
 
|
 
|
 
|-
 
|-
|High grade B-cell lymphoma with 11q aberrations||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|Burkitt-Like Lymphoma with 11q Aberration
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
 
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
+
|Comlete
|
+
|27/01/2022
 
|
 
|
 
|-
 
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
|
+
|3/22/24|| ||Pending|| ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING
|
+
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|
+
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Plasmablastic lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|Plasmablastic Lymphoma
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|
+
|Complete
|
+
|28/03/2022
 
|
 
|
 
|-
 
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING
|
+
| || || || ||GC|| ||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
+
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|
+
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|
+
|(1) Pending + (2) Complete
|
+
|(1) Not ready + (2) 03/28/22
 +
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
 
|-
 
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Intravascular large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING
|
+
| || || || ||GC|| ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
+
|Intravascular Large B-cell Lymphoma
|
+
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|
+
|Complete
|
+
|9/1/22
 +
|Emailed 28/3/2022 for progress update
 
|-
 
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|High-grade B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING
|
+
| || || || ||GC|| ||
|Aiko Otsubo, PhD, Indiana University
+
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|
+
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|
+
|Complete
 +
|16/11/2021
 
|
 
|
 
|-
 
|-
|Burkitt lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||PENDING
|
+
| || || || ||GC|| ||
 +
|Burkitt Lymphoma
 
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
 
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|
+
|Complete
|
+
|28/06/2021
 
|
 
|
 
|-
 
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,840: Line 1,933:
 
|
 
|
 
|-
 
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
|
+
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
 +
| || || || ||GC|| ||
 +
|Polymorphic Post-Transplant Lymphoproliferative Disorders
 
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
 
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
 +
|Completed
 +
|26/4/2022
 
|
 
|
|
 
|
 
 
|-
 
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,854: Line 1,956:
 
|
 
|
 
|-
 
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,861: Line 1,963:
 
|
 
|
 
|-
 
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING
|
+
| || || ||
|
+
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|
+
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|
+
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
 +
|Pending + Completed (03/21/22)
 +
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
 
|
 
|
 
|-
 
|-
|Classic Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease|| || || || || ||GC|| ||
|
+
|NEW (No Prior)
|Patricia V. Hernandez, M.D., Washington University School of Medicine
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|-
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 
|
 
|
 
|
 
|
 
|
 
 
|-
 
|-
|Cold agglutinin disease
+
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
 
|Disease
 
|Disease
 
|
 
|
Line 1,892: Line 1,989:
 
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
+
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
+
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
 
| ||
 
| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG
+
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
|
+
|Primary Amyloidosis
 
|Heather E. Williams, PhD, MS, PgD, ErCLG
 
|Heather E. Williams, PhD, MS, PgD, ErCLG
|
+
|?PENDING<br />
 
|
 
|
 
|
 
|
 
|-
 
|-
|Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG
+
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
|
+
|Light Chain and Heavy Chain Deposition Disease
 
|Chen Yang, MD, PhD, University of Michigan
 
|Chen Yang, MD, PhD, University of Michigan
 +
|Complete
 +
|10/15/2022
 
|
 
|
|
+
|-
|
+
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
|-
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
 
| ||
 
| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Gamma heavy chain disease||Disease|| || || || || ||SG
+
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||PENDING
 +
| || || || ||SG
 
| ||
 
| ||
|
+
|Gamma Heavy Chain Disease
 
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
 
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
|
+
|Complete
|
+
|5/26/2021
 
|
 
|
 
|-
 
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
+
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING
 +
| || || ||
 +
|SG
 +
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
 +
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING
 +
| || || || ||SG
 +
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
 +
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
 +
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
 +
|Pending
 
|
 
|
 
|
 
|
|
+
|-
 +
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
 +
| || || ||
 +
|SG
 +
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
 +
|(1) POEMS Syndrome + (2) TEMPI Syndrome
 +
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
 +
|?PENDING
 
|
 
|
 
|
 
|
 
|-
 
|-
|Plasmacytoma||Disease|| || || || || ||SG
+
|Disease (5th Edition)
| ||
+
|Page Type
|
+
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|
+
|Date Assigned to Author (5th Edition)
|
+
|Target Completion Date (5th Edition)
|
+
|Content Status (5th Edition) (Pending or Complete)
|
+
|Date Completed by Author (5th Edition)
|-
+
|Associate Editor
|Plasma cell myeloma / multiple myeloma||Disease|| || || || || ||SG
+
|Date of Last Editor Review (5th Edition)
| ||
+
|Notes (5th Edition)
|
+
|Correlated Prior Disease Name (4th Edition)
|*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
+
|Correlated Prior Author (4th Edition)
|
+
|Prior Content Status (4th Edition) (Pending or Complete)
|
+
|Prior Date of Last Editor Review (4th Edition)
|
+
|Prior Notes (4th Edition)
|-
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || || ||SG
 
| ||
 
|
 
|Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
 
|
 
|
 
|
 
 
|-
 
|-
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Line 1,990: Line 2,111:
 
----<br />
 
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|-
 
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
+
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 +
|Disease
 +
|Fei Yang, MD
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 +
|SK
 
|
 
|
 
|
 
|
|-
+
|Early T-Cell Precursor Lymphoblastic Leukemia
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
+
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
+
|Pending
|
 
|
 
 
|
 
|
 
|
 
|
 
|-
 
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|
+
|Disease
 +
|Parastou Tizro, MD (trainee);
 +
Sumire Kitahara, MD
 +
|3/17/2024
 
|
 
|
 +
|Pending
 
|
 
|
 +
|SK
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
+
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
|
+
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 +
|T-cell Large Granular Lymphocytic Leukemia
 +
|Michelle Don, MD, MS
 +
|Pending
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
 +
Michelle Don, MD, MS
 +
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 +
|Chronic Lymphoproliferative Disorder of NK Cells
 +
|Michelle Don, MD
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
+
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
|Disease
+
| || || || ||SK|| ||
 +
|Adult T-cell Leukemia/Lymphoma
 +
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
 +
|?Pending
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
 +
|3/22/2024
 +
| || || ||SK|| ||
 +
|Sézary Syndrome
 +
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 +
|Pending
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||PENDING
 +
| || || || ||SK|| ||
 +
|Aggressive NK-cell Leukemia
 +
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
 +
|?Pending
 
|
 
|
|HD
 
|
 
|
 
|
 
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
 
 
|
 
|
 +
|-
 +
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
 +
 +
Andrew Siref, MD
 +
|4/12/2024
 +
| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
 +
|3/22/2024
 +
| || || ||SK|| ||
 +
|Mycosis Fungoides
 +
|Jane Scribner, MD and Daynna J. Wolff, PhD
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|T-prolymphocytic leukaemia
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease|| || || || || ||SK|| ||
|Disease
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|-
|SK
+
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||PENDING
|
+
| || || || ||SK|| ||
|
+
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|
+
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|
+
|Pending
|
 
 
|
 
|
 
|
 
|
 
|-
 
|-
|T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|
+
|3/19/2024
|*Michelle Don, MD, MS
+
| ||Pending
|
+
| ||SK|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
|
+
| || || || ||SK|| ||
|Michelle Don, MD
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024|| ||Pending
 +
| ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
 +
| || || || ||SK|| ||
 +
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 +
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 +
|Pending
 
|
 
|
 
|
 
|
 +
|-
 +
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
 +
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 +
|Enteropathy-Associated T-cell Lymphoma
 +
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 +
|Complete
 +
|1/21/2021
 
|
 
|
 
|-
 
|-
|Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
 +
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 +
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 +
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 +
|Pending
 
|
 
|
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
 
 
|
 
|
 +
|-
 +
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
 +
| || || || ||SK|| ||
 +
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 +
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
 +
|Complete
 +
|9/26/2022
 
|
 
|
 +
|-
 +
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
 +
Michelle Don, MD, MS
 +
|3/19/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 +
|Hepatosplenic T-cell Lymphoma
 +
|Michelle Don, MD, MS
 +
|Complete
 +
|1/21/2021
 
|
 
|
 
|-
 
|-
|Sezary syndrome||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
 +
 
 +
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 +
|Anaplastic Large Cell Lymphoma, ALK-Positive
 +
|Miguel Gonzalez Mancera, MD
 +
 
 +
Sumire Kitahara, MD
 +
 
 +
Cedars-Sinai, Los Angeles, CA
 +
|Complete
 +
|09/23/2022
 
|
 
|
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina
+
|-
 +
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
 +
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 +
|Anaplastic Large Cell Lymphoma, ALK-Negative
 +
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 +
|Complete
 +
|09/23/2022
 
|
 
|
 +
|-
 +
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
 +
|4/1/2024
 +
| ||Pending|| ||SK|| ||
 +
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 +
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
+
| ||Pending|| ||SK|| ||prior authors not available
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
+
|Angioimmunoblastic T-cell Lymphoma
|
+
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
+
| ||Pending|| ||SK|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|
+
| || || || ||SK|| ||
|
+
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|
+
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
 +
|Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Mycosis fungoides||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|
+
|6/25/2023
|Jane Scribner, MD and Daynna J. Wolff, PhD
+
| || || ||SK|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
|
+
|3/19/2024
|Theresa Spivey, MD, Shashirekha Shetty, PhD
+
| ||Pending
|
+
| ||SK|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|
+
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|-
 +
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||prior authors not available
 +
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 +
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 +
|Complete
 +
|11/21/2021
 
|
 
|
 +
|-
 +
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
|-
+
----<br />
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
|-
+
----<br />
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
|-
+
----<br />
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|
 
|
 
|
 
|
 
 
|
 
|
 +
----<br />
 
|-
 
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
 +
|Disease
 +
|PENDING
 
|
 
|
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
 
|
 
|
 
|
 
|
 
|
 
|
|-
+
|GC
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 
|
 
 
|
 
|
 
|
 
|
 +
|Follicular Dendritic Cell Sarcoma
 +
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
 +
|?Pending
 
|
 
|
 
|
 
|
 
|-
 
|-
|Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
 +
|Disease
 
|
 
|
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 
 
|
 
|
 
|
 
|
 
|
 
|
|-
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
 
|
 
|
 +
|GC
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
|
+
|Disease
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
 
 
|
 
|
 
|
 
|
 
|
 
|
|-
 
|Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
 
|
 
|
|*Michelle Don, MD, MS
 
 
|
 
|
 +
|GC
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
 +
|Disease
 
|
 
|
 
|
 
|
Line 2,209: Line 2,585:
 
|
 
|
 
|
 
|
|-
+
|GC
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 
|
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 
|
 
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
 +
|Disease
 
|
 
|
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 
 
|
 
|
 
|
 
|
 
|
 
|
|-
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| ||
 
|
 
|* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG
 
 
|
 
|
 +
|GC
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
 +
|Disease
 
|
 
|
 
|
 
|
Line 2,237: Line 2,617:
 
|
 
|
 
|
 
|
|-
+
|GC
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|
 
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
 
|
 
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
 +
|Disease
 
|
 
|
 
|
 
|
Line 2,251: Line 2,633:
 
|
 
|
 
|
 
|
|-
+
|GC
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
+
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
|-
+
----<br />
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
|-
+
----<br />
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|
 
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 
|
 
|
 +
----<br />
 +
|-
 +
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease|| || || || || ||NA|| ||
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 +
|NEW (No Prior)
 
|-
 
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease|| || || || || ||NA|| ||
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease|| || || || || ||NA|| ||
|
+
|NEW (No Prior)
|*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
+
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|
+
|NEW (No Prior)
----<br />
+
|NEW (No Prior)
|
+
|NEW (No Prior)
----<br />
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Follicular dendritic cell sarcoma
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
 
|
 
|
 
|
 
|-
 
|EBV-positive inflammatory follicular dendritic cell sarcoma
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Fibroblastic reticular cell tumour
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Intranodal palisaded myofibroblastoma
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Littoral cell angioma
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Splenic hamartoma
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
 
|Disease
 
|
 
|
 
|
 
|
 
|
 
|GC
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
 
|
 
----<br />
 
|
 
----<br />
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 
|
 
|
 
|
 
|
 
|
 
|-
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 
|
 
|
 
|
 
|
 
|
 
|-
 
|RASopathies||Disease|| || || || || ||NA|| ||
 
|
 
|
 
|
 
|
 
|
 
 
|}
 
|}

Revision as of 16:23, 16 April 2024

Welcome!

A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.

  • For assignments, please see the "Author" column below (highlighted blue).
  • If empty (no name is present), please volunteer to create content for that disease!
  • If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
  • To volunteer, please [Contact us] with your page of interest.
  • Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.


WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parentheses) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition)(Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition)(Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)



























Clonal haematopoiesis Disease Meenakshi Mehrotra 4/8/24 Pending Fabiola Quintero-Rivera (FQR) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Clonal cytopenias of undetermined significance Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Chronic myeloid leukaemia Disease PENDING FQR Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete Date page was created
Chronic neutrophilic leukaemia Disease PENDING FQR Chronic Neutrophilic Leukemia (CNL) Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally Complete Date page was created
Chronic eosinophilic leukaemia Disease PENDING FQR Chronic Eosinophilic Leukemia, Not Otherwise Specified Chelsea D. Kramish; Daynna J.Wolff complete/pending faculty review
Polycythaemia vera Disease PENDING FQR Polycythemia Vera (PV) Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center Complete
Essential thrombocythaemia Disease PENDING FQR Essential Thrombocythemia (ET) Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN Complete
Primary myelofibrosis Disease PENDING FQR Primary Myelofibrosis (PMF) T. Niroshi Senaratne, UCLA Complete 8/4/2020 before submission
Juvenile myelomonocytic leukaemia Disease PENDING FQR Juvenile Myelomonocytic Leukemia (JMML) Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology

Associate Director | Division of Molecular Pathology, Genetics and Genomics

Duke University Health System Clinical Laboratories

PENDING importing content and reference formatting FQR has emailed SR several times, last 4/20/22
Myeloproliferative neoplasm, NOS Disease PENDING FQR Myeloproliferative Neoplasm (MPN), Unclassifiable Thomas Lee, MD, PhD, University of California, Los Angeles Complete
Cutaneous mastocytosis Disease PENDING FQR Cutaneous Mastocytosis S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD Complete
Systemic mastocytosis Disease PENDING FQR Systemic Mastocytosis Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University Complete
Mast cell sarcoma Disease PENDING FQR Mast Cell Sarcoma Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL Complete
Myelodysplastic neoplasm with low blasts and 5q deletion Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Isolated del(5q) Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG Complete
Myelodysplastic neoplasm with low blasts and SF3B1 mutation Disease PENDING FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with biallelic TP53 inactivation Disease Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with low blasts Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm, hypoplastic Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myelodysplastic neoplasm with increased blasts Disease PENDING FQR Myelodysplastic Syndrome (MDS) with Excess Blasts Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Childhood myelodysplastic neoplasm with low blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Childhood myelodysplastic neoplasm with increased blasts Disease PENDING FQR Refractory Cytopenia of Childhood Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center Complete
Chronic myelomonocytic leukaemia Disease PENDING FQR Chronic Myelomonocytic Leukemia (CMML) Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with neutrophilia Disease PENDING FQR Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Linsheng Zhang, MD, PhD Complete
Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine Complete Date page was created
Myelodysplastic/myeloproliferative neoplasm, NOS Disease PENDING FQR Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia Complete
Acute promyelocytic leukaemia with PML::RARA fusion Disease PENDING Jennelle Hodge (JH)/ Malini Sathanoori (MS) Acute Promyelocytic Leukemia (APL) with PML-RARA Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
Complete 04/26/2021-MS (re-review)
Acute myeloid leukaemia with CBFB::MYH11 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Christine Bryke, MD
Beth Israel Deaconess Medical Center, Boston, MA
Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with DEK::NUP214 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Jennelle C. Hodge, PhD, FACMG Complete 02/24/2021-MS (re-review)
Acute myeloid leukaemia with RBM15::MRTFA fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with BCR::ABL1 fusion Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with BCR-ABL1 Kay Weng Choy MBBS, Monash Medical Centre Complete
Acute myeloid leukaemia with KMT2A rearrangement Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. Complete 03/01/2021-MS (re-review)
Acute myeloid leukaemia with MECOM rearrangement Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Gordana Raca MD PhD, University of Southern California, Los Angeles Complete Need permission for figure? Update WHO?
Acute myeloid leukaemia with NUP98 rearrangement Disease Eric McGinnis, MD 12/20/23 JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with NPM1 mutation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Mutated NPM1 Xinjie Xu, PhD, FACMG Complete Add WHO reference
Acute myeloid leukaemia with CEBPA mutation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Paul Defazio, MSc, Monash Health Complete
Acute myeloid leukaemia, myelodysplasia-related Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute myeloid leukaemia with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute myeloid leukaemia with minimal differentiation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Minimal Differentiation Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine Complete
Acute myeloid leukaemia without maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) without Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute myeloid leukaemia with maturation Disease PENDING JH_MS Acute Myeloid Leukemia (AML) with Maturation Jennelle C. Hodge, PhD, FACMG Complete
Acute basophilic leukaemia Disease PENDING JH_MS Acute Basophilic Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute myelomonocytic leukaemia Disease PENDING JH_MS Acute Myelomonocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute monocytic leukaemia Disease PENDING JH_MS Acute Monoblastic and Monocytic Leukemia Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Acute erythroid leukaemia Disease PENDING JH_MS Pure Erythroid Leukemia Ashwini Yenamandra PhD FACMG Complete
Acute megakaryoblastic leukaemia Disease PENDING JH_MS Acute Megakaryoblastic Leukemia (AMKL) Fei Yang, MD, FACMG
Oregon Health & Science University
Complete
Myeloid sarcoma Disease PENDING JH_MS Myeloid Sarcoma Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine Complete
RESOLVE 4th edition AML-Related NON-WHO entities content Acute Myeloid Leukemia (AML) with Mutated FLT3 + Acute Myeloid Leukemia (AML) with NUP214-ABL1 + Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6 ISSUE- FIX


Resolve Non-WHO entities

Myeloid neoplasm post cytotoxic therapy Disease PENDING JH_MS Therapy-Related Myeloid Neoplasms Shawn A. Silver, DO, Shashi Shetty, Ph.D. Complete Check reference format
Myeloid neoplasms associated with germline predisposition Disease PENDING JH_MS Multiple pages including overview page (Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)) and 6 disease pages ( HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation, HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation, HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation, HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation, HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation, HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation) See links from instructions on the 5th edition page Complete Most were re-reviewed by MS on 03/02/2021 For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
Myeloid proliferations associated with Down syndrome Disease PENDING JH_MS MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO Complete (all three pages)
Myeloid/lymphoid neoplasm with PDGFRA rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Jay Alden, DO Complete
Myeloid/lymphoid neoplasm with PDGFRB rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD Complete
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Disease PENDING FQR Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Yanna Ding, MD PhD Complete
Myeloid/lymphoid neoplasm with JAK2 rearrangement Disease ISSUE- FIX


Resolve Non-WHO entities

FQR Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 (Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)) + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 (Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io) ) - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff Complete
Myeloid/lymphoid neoplasm with FLT3 rearrangement Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes Disease FQR NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia with BCR::ABL1 fusion Disease Tracy Tucker, PhD, FCCMG 4/6/24 Pending JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 Tracy Tucker, PhD, FCCMG Complete
Mixed-phenotype acute leukaemia with KMT2A rearrangement Disease Tracy Tucker, PhD, FCCMG 4/6/24 Pending JH_MS Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged Tracy Tucker, PhD, FCCMG Complete
Acute leukaemia of ambiguous lineage with other defined genetic alterations Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mixed-phenotype acute leukaemia, B/myeloid Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD Complete
Mixed-phenotype acute leukaemia, T/myeloid Disease PENDING JH_MS Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine Complete
Mixed-phenotype acute leukaemia, rare types Disease PENDING JH_MS Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina PENDING
Acute leukaemia of ambiguous lineage, NOS Disease JH_MS NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Acute undifferentiated leukaemia Disease PENDING JH_MS Acute Undifferentiated Leukemia Amelia Nakanishi, MD and Shashi Shetty, PhD Complete Check reference format
CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)



























Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm Disease Greg Corboy (GC) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Blastic plasmacytoid dendritic cell neoplasm Disease PENDING GC Blastic Plasmacytoid Dendritic Cell Neoplasm Hao Liu, MD and Daynna J. Wolff, PhD Complete Previously within myeloid section under JH/MS editors
Langerhans cell histiocytosis Disease PENDING GC Langerhans Cell Histiocytosis Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
Date completed by author: 04/28/2022
Langerhans cell sarcoma Disease PENDING GC Langerhans Cell Sarcoma Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland Complete 5/19/2022
Date completed by author: 04/28/2022
Indeterminate dendritic cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Interdigitating dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Juvenile xanthogranuloma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Erdheim-Chester disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Rosai-Dorfman Disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
ALK-positive histiocytosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Histiocytic sarcoma Disease PENDING GC Histiocytic Sarcoma Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic Complete 10/01/2021 Date completed by author: 10/01/2021
CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



























Reactive B-cell rich lymphoid proliferations that can mimic lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgG4-related disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Unicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Idiopathic multicentric Castleman disease Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-associated multicentric Castleman disease Disease PENDING GC Multicentric Castleman Disease Sudha Arumugam, MD Complete 01/24/2022 Date completed by author: 01/24/2022
B-lymphoblastic leukaemia/lymphoma Disease PENDING Holli Drendel (HD) B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified Holli Drendel PENDING
B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with hypodiploidy Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG Complete
B-lymphoblastic leukaemia/lymphoma with iAMP21 Disease Holli Drendel ?Complete? Looks like tables need more editing. HD B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli] Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte ?Complete
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG PENDING
B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine Complete
B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged Yassmine Akkari Nicolas Millan PENDING
B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Disease PENDING HD B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma PENDING
B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion Disease PENDING HD B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3 Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO PENDING
B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
B-lymphoblastic leukaemia/lymphoma, NOS Disease HD NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
RESOLVE 4th edition ALL-Related NON-WHO entities content B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) ISSUE- FIX


Resolve Non-WHO entities

ISSUE - FIX
Monoclonal B-cell lymphocytosis Disease PENDING; Shashirekha Shetty Shivani Golem (SG) Monoclonal B-cell Lymphocytosis Tsigab Bahta Hagos (trainee) / Shashirekha Shetty PENDING, 4/30/2024 Assigned 12/19/2022 with completion date of 1/19/2023
Chronic lymphocytic leukaemia/small lymphocytic lymphoma Disease Jaime Nagy, PhD, University of Iowa

Renee Eigsti, MD, Pathology Services of Kalamazoo

Honey Reddi, PhD, Belay Diagnostics

Complete SG Already converted to 5th edition Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD
Hairy cell leukaemia Disease SG Hairy Cell Leukemia Snehal Patel, MD, PhD Complete
Splenic marginal zone lymphoma Disease SG Splenic Marginal Zone Lymphoma Snehal Patel, MD, PhD Complete
Splenic diffuse red pulp small B-cell lymphoma Disease SG Splenic Diffuse Red Pulp Small B-cell Lymphoma Snehal Patel, MD, PhD Complete
Splenic B-cell lymphoma/leukaemia with prominent nucleoli Disease SG Hairy Cell Leukemia Variant Snehal Patel, MD, PhD Complete
Lymphoplasmacytic lymphoma Disease PENDING SG (1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia (1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) Complete 4/12/2023 by FQR
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue Disease PENDING SG Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*

Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)

Complete 4/12/23 by FQR
Primary cutaneous marginal zone lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Nodal marginal zone lymphoma Disease PENDING SG Nodal Marginal Zone Lymphoma Andrew Ly, DO and Shivani Golem, PhD, FACMG Complete 5/28/2021
Paediatric nodal marginal zone lymphoma Disease PENDING SG Paediatric Nodal Marginal Zone Lymphoma * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD Complete 11/11/2020
In situ follicular B-cell neoplasm Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG In Situ Follicular Neoplasia Rachel D. Burnside, PhD, MBA, FACMGG Pending
Follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity (1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma (1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida Pending
Paediatric-type follicular lymphoma Disease PENDING SG Paediatric-Type Follicular Lymphoma *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG Complete 8/16/2020
Duodenal-type follicular lymphoma Disease Rachel D. Burnside, PhD, MBA, FACMGG 7/28/2023 Pending SG Duodenal-Type Follicular Lymphoma No prior content
Primary cutaneous follicle centre lymphoma Disease PENDING SG Primary Cutaneous Follicle Centre Lymphoma Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG Complete 09/10/2022
In situ mantle cell neoplasm Disease PENDING SG In Situ Mantle Cell Neoplasia Rina Kansal, MD; Versiti Blood Center of Wisconsin Complete 7/26/2022
Mantle cell lymphoma Disease PENDING SG Mantle Cell Lymphoma Mahsa Khanlari, MD and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas Pending Target completion date 8/15/20
Leukaemic non-nodal mantle cell lymphoma Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Transformations of indolent B-cell lymphomas Disease SG Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma, NOS Disease PENDING GC Diffuse Large B-cell Lymphoma, Not Otherwise Specified Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center Pending Requested to update 14022022
T-cell/histiocyte-rich large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements Disease PENDING GC High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Kate Berry, MBBS, BBus (Hons), Pathology Queensland Complete 24/02/2022
ALK-positive large B-cell lymphoma Disease PENDING GC ALK-Positive Large B-cell Lymphoma Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) Pending Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
Large B-cell lymphoma with IRF4 rearrangement Disease PENDING GC Large B-cell Lymphoma with IRF4 Rearrangement Afia Hasnain, MBBS, PhD Complete 5/26/2021
High grade B-cell lymphoma with 11q aberrations Disease PENDING GC Burkitt-Like Lymphoma with 11q Aberration Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina Comlete 27/01/2022
Lymphomatoid granulomatosis Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive diffuse large B-cell lymphoma Disease Fnu Monika (trainee) + Andrew Siref as mentor 3/22/24 Pending GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Diffuse large B-cell lymphoma associated with chronic inflammation Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fibrin-associated large B-cell lymphoma Disease PENDING GC Note: previously a subset DLBCL assoc with chronic inflam Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fluid overload-associated large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmablastic lymphoma Disease PENDING GC Plasmablastic Lymphoma Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) Complete 28/03/2022
Primary large B-cell lymphoma of immune-privileged sites Disease PENDING GC (1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS (1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital (1) Pending + (2) Complete (1) Not ready + (2) 03/28/22 For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
Primary cutaneous diffuse large B-cell lymphoma, leg type Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intravascular large B-cell lymphoma Disease PENDING GC Intravascular Large B-cell Lymphoma Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy Complete 9/1/22 Emailed 28/3/2022 for progress update
Primary mediastinal large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mediastinal grey zone lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
High-grade B-cell lymphoma, NOS Disease PENDING GC High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) Aiko Otsubo, PhD, Indiana University, Holli Drendel Complete 16/11/2021
Burkitt lymphoma Disease PENDING GC Burkitt Lymphoma Becky Leung, MBBS (Hons), BSc, Pathology Queensland Complete 28/06/2021
Primary effusion lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive diffuse large B-cell lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
KSHV/HHV8-positive germinotropic lymphoproliferative disorder Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Hyperplasias arising in immune deficiency/dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content. What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page. GC
Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders.

Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"

GC Polymorphic Post-Transplant Lymphoproliferative Disorders Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) Completed 26/4/2022
EBV-positive mucocutaneous ulcer Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Lymphomas arising in immune deficiency / dysregulation Disease FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others" GC
Inborn error of immunity-associated lymphoid proliferations and lymphomas Disease FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5. GC
Classic Hodgkin lymphoma Disease PENDING GC Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma (1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma (1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez Pending + Completed (03/21/22) Not completed for checking (1, 3 and 4) + 03/21/22 (2)
Nodular lymphocyte predominant Hodgkin lymphoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Cold agglutinin disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Non-IgM monoclonal gammopathy of undetermined significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Monoclonal gammopathy of renal significance Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Immunoglobulin-related (AL) amyloidosis Disease PENDING SG Primary Amyloidosis Heather E. Williams, PhD, MS, PgD, ErCLG ?PENDING
Monoclonal immunoglobulin deposition disease Disease PENDING SG Light Chain and Heavy Chain Deposition Disease Chen Yang, MD, PhD, University of Michigan Complete 10/15/2022
Mu heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Gamma heavy chain disease Disease PENDING SG Gamma Heavy Chain Disease Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA Complete 5/26/2021
Alpha heavy chain disease Disease SG NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasmacytoma Disease PENDING SG author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Plasma cell myeloma / multiple myeloma Disease PENDING SG Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page (1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants (1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG Pending
Plasma cell neoplasms with associated paraneoplastic syndrome Disease PENDING SG Note: author needs to include POEMS, TEMPI, and look for AESOP content (1) POEMS Syndrome + (2) TEMPI Syndrome (1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD ?PENDING
Disease (5th Edition) Page Type Author (5th Edition) (Note: please indicate trainees in parenthesis) Date Assigned to Author (5th Edition) Target Completion Date (5th Edition) Content Status (5th Edition) (Pending or Complete) Date Completed by Author (5th Edition) Associate Editor Date of Last Editor Review (5th Edition) Notes (5th Edition) Correlated Prior Disease Name (4th Edition) Correlated Prior Author (4th Edition) Prior Content Status (4th Edition) (Pending or Complete) Prior Date of Last Editor Review (4th Edition) Prior Notes (4th Edition)
CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)



























Kikuchi-Fujimoto disease Disease Sumi Kitahara (SK) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Autoimmune lymphoproliferative syndrome Disease Aviv Oren, MD (trainee), Karin Miller, MD 3/25/2024 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-lymphoblastic proliferation Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
T-lymphoblastic leukaemia / lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Early T-precursor lymphoblastic leukaemia / lymphoma Disease Fei Yang, MD Pending SK Early T-Cell Precursor Lymphoblastic Leukemia Fei Yang, MD, FACMG, Kaiser Permanente Northwest Pending
T-prolymphocytic leukaemia Disease Parastou Tizro, MD (trainee);

Sumire Kitahara, MD

3/17/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
T-large granular lymphocytic leukaemia Disease Michelle Don, MD, MS 3/17/2024 6/30/24 Pending SK T-cell Large Granular Lymphocytic Leukemia Michelle Don, MD, MS Pending
NK-large granular lymphocytic leukaemia Disease Hailee St. Louis (trainee);

Michelle Don, MD, MS

3/17/2024 6/30/24 Pending SK Chronic Lymphoproliferative Disorder of NK Cells Michelle Don, MD Pending
Adult T-cell leukaemia/lymphoma Disease SK Adult T-cell Leukemia/Lymphoma Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center ?Pending
Sezary syndrome Disease Daynna J. Wolff, PhD 3/22/2024 SK Sézary Syndrome Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina Pending
Aggressive NK-cell leukaemia Disease PENDING SK Aggressive NK-cell Leukemia Shanelle De Lancy, MD, Shashirekha Shetty, PhD ?Pending
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder Disease Amanda Xu, MD/MSc 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder Disease Ahmed Eladely (trainee),

Andrew Siref, MD

4/12/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Mycosis fungoides Disease Daynna J. Wolff, PhD 3/22/2024 SK Mycosis Fungoides Jane Scribner, MD and Daynna J. Wolff, PhD Pending
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma Disease PENDING SK Primary Cutaneous Anaplastic Large Cell Lymphoma Theresa Spivey, MD, Shashirekha Shetty, PhD Pending
Subcutaneous panniculitis-like T-cell lymphoma Disease Raniah Alamri (Hemepath trainee) 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous gamma/delta T-cell lymphoma Disease Mahzad Azimpouran (trainee); Sumire Kitahara, MD SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma Disease Ahmed Eladely (trainee),

Andrew Siref, MD

4/12/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Primary cutaneous peripheral T-cell lymphoma, NOS Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Indolent T-cell lymphoma of the gastrointestinal tract Disease SK Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Enteropathy-associated T-cell lymphoma Disease Fnu Monika, MBBS (trainee),

Andrew Siref, MD

3/20/2024 Pending SK Enteropathy-Associated T-cell Lymphoma *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD Complete 1/21/2021
Monomorphic epitheliotropic intestinal T-cell lymphoma Disease Fnu Monika, MBBS (trainee),

Andrew Siref, MD

3/20/2024 Pending SK Monomorphic Epitheliotropic Intestinal T-cell Lymphoma Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD Pending
Intestinal T-cell lymphoma, NOS Disease SK Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) Complete 9/26/2022
Hepatosplenic T-cell lymphoma Disease Forough Sargolzaeiaval (trainee);

Michelle Don, MD, MS

3/19/2024 6/30/24 Pending SK Hepatosplenic T-cell Lymphoma Michelle Don, MD, MS Complete 1/21/2021
ALK-positive anaplastic large cell lymphoma Disease Miguel Gonzalez Mancera, MD (trainee)

Sumire Kitahara, MD

Pending SK Anaplastic Large Cell Lymphoma, ALK-Positive Miguel Gonzalez Mancera, MD

Sumire Kitahara, MD

Cedars-Sinai, Los Angeles, CA

Complete 09/23/2022
ALK-negative anaplastic large cell lymphoma Disease Miguel Gonzalez Mancera, MD (trainee)

Sumire Kitahara, MD

Pending SK Anaplastic Large Cell Lymphoma, ALK-Negative Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA Complete 09/23/2022
Breast implant-associated anaplastic large cell lymphoma Disease Lynne Abruzzo, MD, PhD 4/1/2024 Pending SK Breast Implant-Associated Anaplastic Large Cell Lymphoma Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center Pending
Nodal TFH cell lymphoma, angioimmunoblastic-type Disease Rachel Burnside, PhD 7/28/2023 Pending SK prior authors not available Angioimmunoblastic T-cell Lymphoma Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG Pending
Nodal TFH cell lymphoma, follicular-type Disease Rachel Burnside, PhD 7/28/2023 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Nodal TFH cell lymphoma, NOS Disease SK Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD Pending
Peripheral T-cell lymphoma, NOS Disease Bo Hong, MD 6/25/2023 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
EBV-positive nodal T- and NK-cell lymphoma Disease Fnu Monika, MBBS (trainee), Andrew Siref, MD 3/22/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Extranodal NK/T-cell lymphoma Disease Amanda Xu, MD/MSc 3/19/2024 Pending SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Severe mosquito bite allergy Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Hydroa vacciniforme lymphoproliferative disorder Disease SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic chronic active EBV disease Disease Karin Miller, MD 3/25/2024 SK NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Systemic EBV-positive T-cell lymphoma of childhood Disease Karin Miller, MD 3/25/2024 SK prior authors not available Systemic EBV-Positive T-cell Lymphoma of Childhood Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA Complete 11/21/2021
CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)



























Follicular dendritic cell sarcoma Disease PENDING GC Follicular Dendritic Cell Sarcoma Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG ?Pending
EBV-positive inflammatory follicular dendritic cell sarcoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Fibroblastic reticular cell tumour Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Intranodal palisaded myofibroblastoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Littoral cell angioma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Splenic hamartoma Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Sclerosing angiomatoid nodular transformation (SANT) of spleen Disease GC NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
CHAPTER 7 (GENETIC TUMOUR SYNDROMES)



























Fanconi anaemia Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Bloom syndrome Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
Ataxia-telangiectasia syndrome Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)
RASopathies Disease NA NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior) NEW (No Prior)